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Abstract
Evading immune destruction and tumor promoting inflammation are important hallmarks in the development of
cancer. Macrophages are present in most human tumors and are often associated with bad prognosis. Tumor
associated macrophages come in many functional flavors ranging from what is known as classically activated
macrophages (M1) associated with acute inflammation and T-cell immunity to immune suppressive macrophages
(M2) associated with the promotion of tumor growth. The role of these functionally different myeloid cells is
extensively studied in mice tumor models but dissimilarities in markers and receptors make the direct translation to
human cancer difficult. This review focuses on recent reports discriminating the type of infiltrating macrophages in
human tumors and the environmental cues present that steer their differentiation. Finally, immunotherapeutic
approaches to interfere in this process are discussed.
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1. Macrophages
Macrophages are a heterogeneous population of innate
myeloid cells involved in health and disease. Macro-
phages originate from monocytic precursors in the
blood and undergo specific differentiation depending on
local cues in the tissue [1]. Roughly two distinct polari-
zation states are recognized; the classically activated
type 1 macrophages (M1) and the alternative activated
type 2 macrophages (M2). In response to activating dan-
ger signals delivered by bacterial products or IFNg,
macrophages adapt to a M1 phenotype which is tailor-
made to attract and activate cells of the adaptive
immune system. Important features of M1 macrophages
are the expression of iNOS, ROS and the production of
NK and type 1 T-cell stimulating cytokine IL-12. M1
macrophages can phagocytose and kill target cells. M2
macrophages can develop in response to for instance IL-
4 or IL-13[2,3], express abundant scavenger receptors
and are associated with high production of IL-10, IL-1b,
VEGF and matrix metalloproteinases (MMP). M2
macrophages play a role in parasite clearance and
wound healing where they also polarize T cells to Th2
and dampen immune responses [4]. Furthermore
macrophages are antigen presenting cells (APC) that
express class I and class II HLA-molecules and co-sti-
mulatory/inhibitory molecules to instruct T cells, albeit
with lesser efficiency than dendritic cells. Notably, the
terms M1 and M2 are an oversimplification of the
macrophage types that can be detected. Macrophages
display great plasticity and can adapt to a plethora of
activation states ranging between the M1 or M2 pheno-
type depending on the mix of signals in their direct
microenvironment. A number of excellent reviews on
this topic were recently published [2,5-7]. In addition,
fully polarized M1 and M2 macrophages can be redir-
ected in vitro towards the opposite functional phenotype
by treatment of the cells with cytokines [8]. For the
remainder of this review we will refer to M1 and M2
macrophages under the notion that both M1 and M2
will reflect a whole range of functional states of
macrophages.
2. Macrophages in human tumors; clinical impact
& contrasts
For long macrophages are known to play a role in the
development of tumors. This has been exemplified by
their depletion in a number of mouse tumor models [9].
Carcinogenesis is characteristically associated with
macrophage-mediated smoldering inflammation, often
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nity and inflammatory conditions of uncertain origin
[3,11]. In human studies on cancer, macrophages have
predominantly been identified by immunohistochemistry
applying antibodies against CD68 (Table 1) [12-52].
Most studies suggest that a high number of tumor asso-
ciated macrophages is beneficial for tumor growth and,
therefore, associated with disease progression and poor
prognoses for the patient (reviewed in [53]). However,
sometimes a high number of infiltrating macrophages
correlates with better prognosis. For instance in human
papilloma virus (HPV) induced cervical intraepithelial
neoplasia macrophage infiltration was reported to corre-
late with disease progression [23]. Yet, in cervical can-
cers the number of stromal macrophages positively
correlated with the intratumoral expression of IL-12p40,
which itself was associated with a favorable overall sur-
vival of patients [54]. In lung cancer, higher numbers of
IL-10+ CD68+ macrophages correlated with poor survi-
val of patients with late stage disease [51]. However,
another study showed that high macrophage numbers
correlated with better survival. Importantly, in this study
the polarization of the macrophages was determined
and this revealed that improved survival was associated
with a high M1/M2 ratio [37]. The type of macrophages
studied thus may explain the apparent discrepancy
between studies. Clearly, tumors can give rise to a het-
erogeneous population of tumor-infiltrating myeloid
cells that differ at the molecular and functional level as
a result of different instructions given by the local
microenvironment [55-57]. The detection of macro-
phages on basis of CD68 does not allow identification of
these distinct subsets and this deficit has been recog-
nized in the field. Recent studies often show that antibo-
dies to 2-3 different markers are combined (Table 1).
Unfortunately, there are not many studies that apply the
same set of markers to study the subsets of tumor-infil-
trating macrophages. Furthermore, sometimes combina-
tions of different antibodies were not used to
discriminate between macrophage subsets but to differ-
entiate between the expression of certain types of
immune regulatory molecules by macrophages and
tumor cells (e.g. PD-L1) [58,59]. It should be noted that
the predominant detection ofM 2m a c r o p h a g e sr e f l e c t s
the late stage of tumor progression since the presence,
type and role of macrophages in lower staged neoplasias
is only marginally studied [23,60].
Alternatively, the number of tumor associated macro-
phages may form an epiphenomenon reflecting an
inflamed tumor micro-environment in which many
types of immune cells can be found [48,61]. This may
comprise strong infiltration by regulatory T cells that
exert a negative impact on clinical outcome. On the
other hand it may also include the infiltration of tumors
by T cells with cytotoxic function and a type 1 cytokine
profile [62,63]. Moreover, macrophages do not only con-
tribute to the local inflammation but also impair the
activation of an effective anti-tumor T-cell response in
tumor draining lymph nodes by inducing apoptosis [64].
3. Identification of distinct human macrophage
subsets
Macrophages can be identified by the expression of
transcriptional factors, cell surface markers, the produc-
tion of cytokines and their function in vitro.I nh u m a n s ,
the detection of tissue associated monocytes and macro-
phages in situ, is predominantly based on the use of
antibodies to the glycoprotein CD68. However, antibo-
dies to the LPS-co receptor CD14 or to HLA class II,
represented by HLA-DR, are also used. Potentially, anti-
bodies to the Fcg-receptors can also be used, as these
receptors - used to bind antibody-bound particles - are
highly expressed by macrophages. So far, only antibodies
to FcgRIII (CD16) have been used for the flow cyto-
metric analysis of macrophages in vitro [65]. Newly
added to the list of antibodies are those that target
macrophage subset-specific markers. M2 macrophages
express high levels of CD163, a hemoglobin-scavenger
receptor, and can be used to discriminate between M1
and M2 macrophages (Table 1 and [66,67]). Tolerogenic
macrophages and DC display higher levels of the man-
nose receptor (CD206) which is another scavenger [5].
In addition, the macrophage scavenging receptor 1
(CD204) is used as a specific M2 macrophage marker
(Table 1). Thus far no unique markers for M1 macro-
phages are described. A list of markers which are cur-
rently applied to detect and distinguish between M1 and
M2 macrophages is shown in table 2[5,6,29,53,67-77].
Matters, however, become more complicated when
these macrophages become activated either via their
pathogen-associated molecular pattern (PAMP)-recep-
tors or upon cognate interaction with other immune
cells. We and others have observed that activation
results in loss of expression of the typical macrophage
(e.g. CD14) and M2 markers (e.g. CD163, CD16 [65,66]).
This implies that the use of a combination of different
antibodies against cell surface markers to detect distinct
macrophage subsets polarization will always be imper-
fect, albeit able to deliver much more information as in
previous studies. To overcome this problem the expres-
sion of molecules that are directly related to macro-
phage function can be studied. Matrix
metalloproteinases (MMPs) are proteolytic enzymes that
degrade extracellular matrix and the basic membrane
and are involved in tissue remodeling, tumor invasion
and neovascularization of tumors. For instance, MMP 1,
2 and 9 are abundantly produced by M2 macrophages.
The expression of MMPs in combination with CD68 or
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Page 2 of 13Table 1 Tumor associated macrophages in situ
Organ Cancer type n
1 Method
2 Markers Macrophage infiltrate? Link to prognosis
3 Ref
Lymphnode Hodgkins lymphoma 265 TMA IHC CD68 CD163 Using a 5% of cells is positive
cut-off; 80% is CD68+ cell
positive and 64% is CD163+
No link 7
Hodgkins lymphoma 130 and 166 IHC CD68 MMP11 Using a 5% and 1% of cells is
positive cut-off;72% is CD68+
cell positive and 41% positive
for MMP-11
High CD68+ MF or high
MMP-11 expression
correlates with poor
disease specific survival
40
Hodgkins lymphoma 105 TMA IHC CD68 42% has high MF infiltration (>
0,82% of total cells is positive
for CD68)
High infiltration
correlates with higher
age and poor survival
(also in the younger
patients)
42
Colon CRC 17 IHC CCL2 CD68 IL-8 Mean MF number in tumor 8/
mm3, in stroma 44/mm3 and
necrotic area´s 44/mm3 and all
tumors are high IL-8 postive
Tumor cell produced
CCL2 correlates to MF
count and advanced
disease stage
8
CRC 478 IHC CD68 76% has high MF infiltration at
tumor front
High MF count at
tumorfront associates
with better prognosis
16
CRC 118 IHC CD68 MMP-2
MMP-9
47% has high MF numbers and
this correlates with expression
of MMP-2 and MMP-9
Intratumoral TAM
correlate with invasion,
LN status and staging
21
CRC 40 DIHC CD68 S100
CD163
In all samples MF infiltration,
more in stroma than in tumor
beds. Mean is 12/15 per high
power field.
Significant better
survival for patient with
high DC count and
trend for high CD163
count.
29
CRC 159 IHC CD68 Clever-1/
Stabilin-1 CD206
CD3+
98% has peritumoral
macrophages in 10 tested
tumors all MF are CD206/
Clever-1 dubbelpositive
High peritumoral CD68
better prognosis; low
intratumoral M1/M2
ratio more recurrent
disease
52
CRC metastasis in
liver
15 IHC CD68 CD163
CXCL-10 CXCR-4
CXCL-12 Her1
Her4 HB-EGF
CD68, CXCL-10, CD163 positive
cells are found in al lesions
– 35
Intestinal
tract
GIST 47 (19
metastatic)
FIHC CD68 CD163
CD14 CD1a CD20
S100, HLA-DR
CD3 CD8 FoxP3
CD33
High infiltrate in primary lesion
tumors (2,7%) and metastatic
lesions (4,9%) of CD163+
macrophages.
Presence of M2 is
correlated with FoxP3
positive infiltrate
43
gastric cancer 105 IHC ZG hypoxia CD68
CD34 VEGF
MMP2 +9
More macrophages in hypoxic
area’s
Hypoxia and more
macrophages correlates
with shorter survival
34
Lung NSCLC 100 DIHC CD68 HLA-DR
CD163
Of CD68 positive MF 70%
express CD163, 3% is positive
for CD163 and HLA-DR
Patients with long
survival have higher
number of M1 type MF
28
NSCLC 50 DIHC CD68 IL-10 95% of IL-10 positive cells in
advancing tumor margin is of
MF origin
High IL-10 positive MF
in advanced disease and
therefore correlated to
poor prognosis
46
NSCLC 40 IHC CD68 DR CD163
VEGF TNFa iNOS,
Less MF infiltrate in tumor
islets of patient with shorter
survival (all MF types)
More MF in tumor islets
correlate with better
prognosis
32
NSCLC 20 IHC CXCR-1,2,3 ,4,5
and CCL-1
CXCR-3 is positively correlated
with MF number as
determined in (ohri ERJ 2009)
Higher CXCR-2, CXCR-3
and CCL-1 expression in
patients with extended
survival
33
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Page 3 of 13Table 1 Tumor associated macrophages in situ (Continued)
Mesothelioma pleural
mesothelioma
52 (+ 7
flowcytometry)
IHC CD68 CD163
CD206 CD124
CD68+ MF comprised 27 % of
tumor area, 7 tumors tested by
flowcytometry; MF express
high levels of M2 markers
High MF number in
non-epithelial tumors is
associated with bad
prognosis
10
Breast breast CA 110 + 106 IHC CD68 anti-PCNA
(proliferation)
Double positive proliferating
macrophages are found in
most tumors
High number of
proliferating
macrohpages associated
with decreased survival
12
breast CA 127 IHC CD68 CD163
MAC387
Using a 25% surface area
cut0off; 48% has high
infiltration of CD163+ cells,
MAC387 expression in 12%
High CD163 correlates
with more distant
disease recurrence
38
Breast and
Colon
primairy metastatic
lesions
49 breast and
12 colon
metastasis
IHC FCgRIIIa, FCgRII,
CTSL1, CD163
Signature in primary lesion is
the same as in corresponding
metastatic lymphenode
– 44
Ovarian and
Peritoneum
ovarium carcinoma MS
DIHC/
FIHC
levels of
eicosanoids
(PGE2) and other
related enzymes
High levels of eicosanoids in
tumors, peritumoral CD163+
MF express COX and PGES
– 17
epithelial ovarian
carcinoma
40 (21 serous,
19 mucinous)
IHC CD68 CD163
CD204 CSF-1
M2 cells present in stomal
compartment of all patients,
MF number and CSF-1 increase
with disease progression
High M2 correlates with
disease stage
22
ovarium CA 60 +12 FIHC
DIHC
Flow
B7-H4 HAM56
CD3
70% of intratumoral MF
express B7-H4
– 24
ovarium CA 103 DIHC B7H4 HAM56
(CD4 FoxP3)
Higher expression of B7-H4 on
macrophages in advanced
stage and correlate with the
presence of regulatory T cells.
High B7-H4 expression
on MF correlates with
poor survival
25
Uterus endometrioid
carcinoma
64 IHC CD163 CD31 HIF-
1A
Only invasive tumors have
high MF infiltration, more
HIF1A and higher vessel
density
In paired LN metastatic
lesion same pattern for
CD163 and CD31 is
found
14
endometrioid adeno
CA
61 IHC MMP-12 en CD68 Higher MF and MMP-12
expression in more advanced
disease
Higher MMP-12 and MF
in advanced disease
45
Cervix CIN, HSIL, CxCa 86 IHC CD68 Number of MF correlates with
disease progression
High MF number
predicts disease
progression
18
Skin stage 1/2 melanoma 227 blood 190
tumors
IHC
ELISA
CD68 CD163 and
soluble CD163
67% has dense infiltration with
CD163 cells at invasive front
and stroma
High CD163 in tumor
front or stroma
correlates with poor
survival
20
metastatic
melanoma
6 FIHC CD45 CD68
CD163 CD209
CXCL-12
60% of perivascular TAM
expres CXCL-12
– 37
Prostate first diagnostic
screening;
92 of which
30% has
prostate ca
IHC CD68 CD204 Less CD204 positive cells is
associated with development
of prostate CA
– 31
needle biopsies
prostate
135 IHC CD204 CD204 positive cells present in
all samples
– 41
Eye eye melanoma 43 FIH CD68 CD163 Most MF are double positive,
more macrophages in
monosomy of chromosome 3
Less macrohpages is
associated with better
survival
9
Kidney renal cell carcinoma 43 DIH CD209 CD14
CD163
Most CD209+ cells were also
CD14 and CD163+
– 15
Liver hepatocellular
carcinoma
63 IHC CD68 B7-H1 (PD-
L1)
High B7-H1 expression on
tumorcells if high macrophage
infiltration (48% of patients)
– 13
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tumors (Table 1). The functional activity of M1 macro-
phages is characterized by the production of reactive
oxygen species (ROS) and nitric oxide (NO). However,
due to their short life-span and therefore enzymatic
activity these molecules are hard to detect. Instead, the
detection of with this function associated enzymes like
t h ei n d u c i b l en i t r i co x i d es y n t h a s e( i N O S )i su s e di n
some of the studies (Table 1).
In contrast to studies on macrophages in situ it is
easier to assess macrophage function in vitro. All macro-
phages can phagocyte particles and apoptotic cells.
Upon activation M1 macrophages will respond with an
oxidative burst by the production of ROS and NO via
iNOS as well as by the release of interleukin-12, known
for its type 1 T-cell polarizing capacity. The use of NO
to identify human M1 macrophages is somewhat
debated as it was not detected in human macrophage
cultures but abundantly found in tissues as detected by
IHC (reviewed [72]). Therefore, in vitro studies on
human macrophages focus mostly on the production of
IL-12 and IL-10 to discriminate between M1 and M2
subsets [66,67,78,79].
New markers that may assist to discriminate M1 from
M2 macrophages are typical transcription factors
expressed by these cells [80]. M1 cells highly express
IRF-5, a transcription factor that is involved in stimulat-
ing the production of type 1 interferon while repressing
the production of IL-10. Forced expression of IRF-5 in
M2 macrophages switches them to M1 macrophages.
Genetic polymorphisms that induce overexpression of
IRF-5 mRNA in human auto-immune pathologies like
SLE and multiple sclerosis illustrate the link between
high IRF-5 expression and type 1 inflammation in
human beings (reviewed in [81,82]). Secondly, the signal
transducer and activator of transcription (STAT) protein
family is associated with the function of immune cells.
Cytokine induced phosphorylation and nuclear expres-
sion of STAT1 is associated with a type 1 pro-inflamma-
tory phenotype whereas STAT3 resembles an anti-
inflammatory phenotype. STAT3 expression is often
found in tumors and tumor-infiltrating macrophages
and is induced by IL-6 and IL-10 [77].
Last but not least, macrophages produce chemokines
to attract other immune cells and the type of these che-
mokines may offer help to distinguish between the
Table 1 Tumor associated macrophages in situ (Continued)
intra-hepatic
cholangiocarcinoma
39 IHC CD68 CD163
CD34 FoxP3
50% of patients has high M2
infiltration and this correlates
with vessel density and FoxP3+
numbers
High CD163+ correlates
to poor disease free
survival
19
Brain glioma 79 DIHC CD68 CD163
CD204 M-CSF
Higher macrophage infiltration
and shift towards M2 type in
advanced stage
More CD163+CD204+
macrophages and high
M-CSF in advanced
stages
23
Pancreas pancreatic head
cancer invasive
ductal cancer
76 DIHC CD68 CD163
CD204
42% shows high M2 infiltration
perivasculair in invasive front
High M2 infiltration
associated with LN
metastasis
26
Soft tissues leiomyosarcoma 76
gynecologic
and 73 non-
gynaecologic
TMA IHC CD68 CD163 44% of patients has dense
infiltrate with CD163+ cells
In non-gynecologic
tumors, high CD163+
number correlate with
poor prognosis
27
Peripheral
Lymphoma
angioimmunoblastic
T cell lymphoma
42 DIHC CD68 CD163 Only invasive tumors have
high MF infiltration, more
HIF1A and higher vessel
density
CD163/CD68 ratio
correlates to overall
survival
30
Thyroid anaplastic carcinoma 27 IHC NOX-2 P22-phox
CD68 CD163
All tumors display a very dense
network of TAM, 57% of tumor
is TAM
– 11
thyroid cancer well/poor/
anaplastic 33/
37/20
IHC CD68 CD163 27/54/95% has high CD 68
macrophage infiltrate thus
more macrophage in advanced
stage
– 36
Salivary gland salivary gland 35 IHC CD68 CD34
VEGFa
High infiltration with CD68 in
50% of patients
– 39
1. Number of patients analyzed
2. TMA=Tissue Micro Array, IHC= immunohistochemistry, DIHC = double staining for immunohistochemistry, FIHC=fluorescent immunohistochemisty staining,
ZG= zymography MS=mass-spectometry, Flow=Flowcytometry
3. Macrophage infiltrate was correlated to survival, – = not conducted
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Page 5 of 13macrophage subsets. For example, activated M1 macro-
phages produce CXCL-10 (IP-10) in order to attract CD8
and Th1 CD4+ T cells. M2 macrophages attract immune
cells by the production of CCL-22 and CCL18. Differen-
tiation between human M1 and M2 macrophages on the
basis of their chemokine production has so far only been
evaluated in vitro [18,79]. In vivo, most studies focused
on the total tumor-derived chemokinome and, therefore,
the exact role of macrophage-produced chemokines to
attract immune cells is not clear yet.
It has to be said that there are a number of reports
suggesting that also tumor cells and monocytes might
express CD163, the detection of which depends on the
antibody that is used [43,68]. Furthermore, MMPs are
reported to be produced by tumors as well [50]. MMPs
are thought to contribute to tumor progression, how-
ever, there is accumulating evidence that MMPs may
also confer tumor protection [70]. In our opinion, care-
ful assessment of macrophages in the tumor requires
preferably the use of 3 markers to identify macrophages
and their functional profile.
4. Induction of tumor associated macrophages
Tumors require nutrients, oxygen and the ability to dis-
charge metabolic waste and carbon dioxide. These needs
are addressed by tumor associated neovascularization
[11]. Macrophages are the perfect help in this process,
especially the wound-healing subset, since they are
equipped to remodel tissue and produce VEGF. How
tumors attract these myeloid cells has been excellently
reviewed before [83].
CCL-2 produced by tumor cells and tumor associated
cells attracts and shapes myeloid cells and interferes
with osteoclasts in bone- metastatic disease [84,85].
Blocking CCL-2 reduced the number of tumor-infiltrat-
ing macrophages in pre-clinical animal studies. Sec-
ondly, the transcription factor Hypoxia Inducible
Factor-1 (HIF-1), highly expressed under hypoxic condi-
tions, regulates the attraction of monocytes and macro-
phages into the tumor amongst others by induction of
Colony Stimulating Factor-1 (CSF-1/M-CSF) [83].
Many studies have been conducted to determine
which factors induce macrophage differentiation upon
arrival in the tumor. The levels of several cytokines
were measured in tumor fluids, in ascites or in blood.
Furthermore, the gene expression profiles of tumor cells
have been analyzed. Interleukin-6 (IL-6) was often
reported to be present in tumor fluids and was a pro-
duced by many tumor derived cell lines. IL-6 is a cyto-
kine involved in chronic inflammatory diseases such as
rheumatoid arthritis [86]. A number of studies on the in
vitro differentiation of M2 macrophages - when mono-
cytes or immature DC are exposed to tumor cell super-
natant derived from lung, ovarian or cervical cancer cell
lines - showed that this differentiation depended on IL-
6. In nearly all cases IL-6 was shown to act in synergy
with other factors [66,78,79,84,87]. Binding of IL-6 to its
receptor results in activation of STAT3 in immune cells
and consequently in the suppression of immune media-
tors that activate the immune response [77].
CSF-1 (M-CSF) mediates, besides being a chemo
attractant, the differentiation of monocytes into CD14
Table 2 Markers used to identify human tumor associated macrophages
Molecule Function in situ
1 in vitro
2 Expression
3
monocytes M1 M2 other ref
CD68 Glycoprotein for adherence IHC x x x 53
CD14 LPS co-receptor IHC Flow x x x 67.73
CD163 Scavenger receptor hemoglobulin IHC Flow +/- +/- xx 5,63,75,76
CD206 Mannose receptor Flow x xx 6
MMP-2 Matrix metalloproteinase IHC Digestion x Tumor cells 70
MMP-9 Matrix metalloproteinase IHC Digestion x Tumor cells 70
HLA-DR Antigen presentation molecule IHC Flow x x x Immune cells
CD204 Macrophage scavenger receptor 1 IHC x x Tumor cells 71
B7H4 Inhibiting costimulatory molecule IHC Flow x Tumor cells 29
CD11b Mac-1 Flow x x x 73.76
FRb Folate receptor beta Flow x 74
STAT-3 Transcription factor IHC Flow x Tumor tissue 77
iNOS Nitric Oxide Synthase IHC x 72
IL-12p70 Interleukin IHC ELISA x xx 67.69
IL-10 Interleukin IHC ELISA x x xx Tumorcells 67
1. IHC = Immunohistochemical staining
2. Flow = immunofluorescent flowcytometry, ELISA = Enzyme-Linked Immunosorbent Assay, Digestion = collagen digestion assay
3. × = present on cell subset, XX = highly expressed or produced
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Page 6 of 13+CD163+CD206high M2 macrophages in vitro [67]. A
similar dual role has been suggested for VEGF which
acts as an angiogenic factor when secreted by wound
healing macrophages but which can also impair APC
differentiation when secreted by tumor cells [88].
The inflammation-inducible cyclo-oxygenase-2 (COX-
2)-derived prostaglandin E2 (PGE2) is overexpressed by
several human tumor-types [89]. The role of COX and
PGE2 in oncogenesis has been well investigated in col-
orectal cancer. Blocking this pathway prevented onco-
genesis in the low-intestines [90]. In vitro the addition
of PGE2 to IL-4/GM-CSF stimulated monocytes skews
their differentiation towards M2 macrophages
[66,78,91,92]. Notably, overexpression of COX-2 in
human lung cancer cells resulted in the production of
IL-6 and the subsequent phosphorylation of STAT3.
This rendered the tumor cells more resistant to apopto-
sis as well as increased their VEGF production [93].
Human tumors express and release high levels of Heat
Shock Protein 27 (HSP27) (reviewed by [94]). The addi-
tion of soluble HSP27 to monocytes in vitro directed
their differentiation to macrophages with an immune
tolerizing and proangiogenic phenotype [95].
Thus, inflammatory mediators attract myeloid cells to
the tumor and direct their differentiation towards tumor
promoting macrophages (Figure 1). The macrophage in
the tumor tissue is subject to local levels of many fac-
tors that lead to a great variety in myeloid cell subsets
even within a single tumor. Interestingly, most described
factors are also produced by macrophages suggesting a
feed forward loop.
5. Macrophages and adaptive immune cells in
cancer
The plasticity of macrophages has been shown in vitro
but whether M2 macrophages can revert to M1 and vice
verse within the tumor environment is an emerging
question. In vitro, exposure of murine macrophages to a
type 1 cytokine environment skews them towards M1
macrophages. In contrast, the macrophages adapted a
M2 phenotype upon exposure to IL-10 [8,96]. Adapta-
tion to a particular phenotype was reversible by subse-
quent changes of the cytokine milieu [96]. Also human
macrophages show great plasticity with respect to
macrophage phenotype following stimulation with anti-
or pro-inflammatory stimuli [97]. IFNg,w h i c hw a so r i -
ginally called macrophage activating factor, plays a
major role in the differentiation towards M1 macro-
phages. It’s produced by both innate and adaptive
immune effector cells, including CD8 T cells and several
IFNγ
CD14
HLA-DR CD68
CD163
CD204
B7H4
PD-L1
CD40-CD40L
HIF-1
CCL-2
CSF-1
IL-6
PgE2
HSP-27
pSTAT3
VEGF
MMP-2&9
IL-10
IL-12
I I I I I
I I I II II II I I I
III
V
IV
Figure 1 Macrophages and T cells in the tumor micro milieu. Tumors actively attract myeloid cells by the secretion of chemokines which is
amongst others driven by hypoxia (I). Once myeloid cells have arrived in the tumor micro milieu several tumor cell produced factors drive the
differentiation into a range of different types of macrophages, including M2 macrophages as a consequence of high STAT3 phosphorylation (II). M2
macrophages produce tumor promoting factors, express inhibitory molecules and upon activation produce anti-inflammatory cytokines and
metalloproteinase that hamper T-cell function and promote tumor growth (III). Activation of M2 macrophages in the presence of IFNg - for instance
following cognate interaction CD4+ type 1 helper T cells - switch M2 macrophages to pro-inflammatory activated M1 macrophages (IV). M1
macrophages alter the immune suppressed micro milieu by producing IL-12 helping anti-tumor T cells as well as directly attack tumor cells (V).
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IFNg induces STAT1 and IRF-5 signaling-mediated type
1 cytokine production. Dulluc et al. comprehensively
showed that IFNg can prevent and reverse the M2-skew-
ing effect of ascites from patients with ovarian cancer.
Furthermore, pre-treatment of M2 macrophages with
IFNg results in a macrophage type that produces more
IL-12 and less IL-10 upon activation with several innate
stimuli [79].
Cognate interaction with CD4+ helper T cells consti-
tutes a powerful activation signal for antigen presenting
cells. The signal is delivered via CD40-CD40L interac-
tion following T-cell receptor mediated MHC class II-
presented antigen recognition. CD40L and IFNg can
activate in synergy but do not have to come from the
same CD4 T cell. Exposure of APC to IFNg-producing
CD8+ T cells and CD40-L+ CD4 T cells allows APC to
produce IL-12 and to become strong promoters of Th1
responses [98,99]. We showed recently that tumor
skewed IL10-producing M2 macrophages can fully
revert to IL12-producing M1 macrophages following
interaction with CD4+ Th1 cells or with CD40-L-
expressing cells in the presence of IFNg [66]. Notably, in
this in vitro study CD40-CD40L interaction resulted
only in a strong activation signal for macrophages that
was required but not sufficient to change the macro-
phage subset. Interestingly, we have observed that a
minor population of tumor-infiltrating human CD8+ T
cells expresses CD40-L upon activation [100]. This
poses the question whether certain populations of intra-
tumoral CD8 T cells can mediate the same effect on
macrophages as CD4+ Th1 cells. The important role of
T cells in instructing APC is further supported by stu-
dies showing that freshly isolated and activated blood-
derived regulatory T cells skewed monocytes to M2
macrophages, which were able to produce high levels of
IL-10 when stimulated with LPS [101]. The regulatory T
cells, defined as CD4+CD25high cells, exerted their
effect via the secretion of IL-13, IL-4 and most impor-
tantly IL-10 that was produced upon T-cell activation
[101].
Mouse tumor-models support the significance of cog-
nate interactions between CD4 T cells and macrophages.
In an aggressive breast tumor-mouse model IL-4-produ-
cing CD4+ T lymphocytes indirectly promoted invasion
and subsequent metastasis of mammary adenocarcino-
mas by regulating the phenotype and effector function
of tumor-associated macrophages [102]. In another
study, myeloma tumors were infiltrated by macrophages
within 3 days, followed by tumor-specific CD4+ Th1
cells at day 6 after which the macrophages started to kill
tumor cells [103]. This indicates that during early tumor
development a Th1-macrophage response controls
tumor outgrowth. Thus the type of T cell that interacts
with tumor associated APC influences the polarization
and function of the APC. Depending on the type of T
cell, APC can swap their function allowing them to sup-
press or to stimulate immunity and vice verse.
Studies that evaluate the type of macrophages in rela-
tion to the number and type of T cells in patients are
scarce. In ovarian cancer high numbers of B7H4 expres-
sing immunosuppressive macrophages correlated with
increased numbers of FoxP3+ T cells [30]. Accordingly,
in gastrointestinal stromal tumors the number of CD163
+M2 macrophages correlated with CD3+FoxP3+ regula-
tory cells [48]. A similar relation was reported for
hepato-cholangiocarcinomas [24]. In contrast, in Hodg-
k i nl y m p h o m aa ni n v e r s ec o r r e l a t i o nw i t hC D 6 8 +
macrophages and FoxP3+ T cell numbers was reported.
Here macrophages positively correlated with higher
numbers of granzymeB and PD-1 expressing T cells
instead. Alas, in this last study the type of infiltrating
macrophages was not evaluated but the number of
macrophages correlated to poor prognosis suggesting a
M2 type of infiltration [47]. Finally, tumor-infiltrating
macrophages were reported to attract IL-17+ CD4 T
cells in liver carcinoma, thereby sustaining inflammation
and supporting tumor promotion [104]. A recent study
showed that a high number of macrophages and CD4+
T cells was correlated to a bad prognosis in breast carci-
noma whereas CD8+ T cell dominance related to good
prognosis [105]. Based on the MMTV-PyMT breast
tumor mouse model, in which these authors also found
a relation between macrophages, CD4 T cells and poor
outcome, the CD4 T cells are likely to be Th2 cells
[102]. Although these studies show that the number of
infiltrating macrophages is related to the number of
(regulatory) T cells it is not clear if these cells interact
and what the outcome of interaction is with respect to
macrophage function. For that the functional properties
of all infiltrating T-cell subsets should be evaluated.
6 Repolarization of macrophages - a way to treat
cancer?
The strong infiltration of human tumors by activated
CD8+ cytotoxic lymphocytes (CTL) and CD4+ helper T
(Th) cells but not immune suppressive cells such as reg-
ulatory T cells, M2 macrophages and myeloid derived
suppressor cells is a hallmark for improved survival after
therapy (reviewed by [106]). The treatment of cancer
may take advantage of therapies that interfere with M2
macrophages, if combined with standard or immu-
notherapeutic regimens. Therapeutic modalities may
attack at several levels; the attraction, the differentiation
or the activation of macrophages.
One therapeutic option is to interfere at the level of
macrophage attraction and differentiation by abrogation
of the PGE2, IL-6 and STAT3 activation loop. This may
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tolerogenic macrophages as well. Several trials were con-
ducted in which PGE2 production was inhibited by
blocking of the COX-2 enzyme, often in combination
with standard cytotoxic therapy [90,107]. Since all stu-
dies were initiated to block the paracrine loop on tumor
cells not much is documented about the immunological
effects let alone macrophage differentiation. One report
mentions high immune cell infiltration, including
macrophages upon 3 days of treatment with the COX-
inhibitor [108].
A second strategy to interfere with immune cells in the
tumor micro milieu is the blockade of cytokines secreted
by the tumor or immune cells (e.g. M-CSF or IL-6).
Recently, a phase II trial in patients with ovarian carci-
noma was reported were the anti-IL-6 antibody siltuximab
was tested [87]. The goal in this study was to deprive the
tumor from growth factors and to prevent the differentia-
tion of M2 macrophages. It might prove difficult to reach
high enough antibody titers to block cytokine levels as
macrophages tend to accumulate in poorly vascularized
tumor areas [83]. Blocking of the cytokine receptors is not
advised as membrane bound antibodies may activate type
2 macrophages via cross linking of the FcgReceptors and
thereby activate tumor promoting cascades. This was
recently demonstrated in vitro for the humanized Fc
region optimized antibody cetuximab that binds the EGF-
Receptor at the tumor cell surface and which caused acti-
vated M2 macrophages to produce IL-10 following the
cross-linking of Fc-receptors [65].
All above mentioned strategies aim to inhibit the
induction of M2 macrophages but do not reprogram
M 2m a c r o p h a g e so n c et h e ye x i s t .In vitro macrophages
can adapt to another phenotype upon a strong polariz-
ing stimulus as discussed before [97]. Therefore, deliver-
ance of a local APC-activating stimulus may be an
attractive option. Macrophages highly express PAMP-
receptors and several agonists for TLR and NOD-recep-
tors are currently under clinical investigation for the
treatment of cancer. For instance, easy accessible (pre-)
malignancies have already been treated with TLR7 ago-
nists [109]. We showed that activation of M2 macro-
phages in vitro by a number of different TLR agonist’s
results in the loss of expression of typical M2 markers
but did not alter their typical M2 function [66]. Follow-
ing this principle through made us realize that it also
bears impact on other studies in this field. The group of
Zitvogel extensively studied the effects of chemotherapy
a n ds h o w e dt h a tH M G B - 1r e l e a s e df r o md y i n gt u m o r
cells acted as a TLR4 agonist to activate APC [110]. The
specific immune modulating properties of proteins
released from dying tumor cells (e.g. HMGB-1) on the
activation of M2 macrophages via PAMP-receptors is
not yet studied.
Reprogramming of M2 to M1 type macrophages not
only requires receptor-mediated activation signals but
the presence of polarizing cytokines (e.g.I F N g)a sw e l l .
TLR are also expressed by T cells and stimulation mod-
ulates T-cell responses upon TCR triggering [111]. At
the T-cell population level this may result in the
enhanced production of IFNg by T cells but also the
downregulation of regulatory T-cell function [111]. One
can envisage that if TLR-agonists not only activate
macrophages but also T cells to produce IFNg this will
result in reprogramming of the macrophages. On the
other hand, our own studies on the TLR expression by
patient derived tumor-antigen-specific CD4+ T-cell
clones, including helper T cells and regulatory T-cell
clones, revealed that human T cells express a number of
different TLRs at the mRNA level and that the TLR
expression pattern differed per CD4+ T-cell clone inde-
pendent of their function. When these CD4+ T-cell
clones were tested in various activation (proliferation,
cytokine production) and suppression assays no consis-
tent gain (proliferation/IFNg production) or loss in func-
tion was observed due to the presence of TLR-agonists
either with or without TCR triggering. This suggests
that TLR may not play a major role when CD4+ T cells
are fully polarized already (unpublished observations). It
is, therefore, questionable whether the application TLR
agonists may result in repolarization of macrophages.
A recent study revealed that activation of macro-
phages by the infusion of antibodies against CD40 may
induce macrophage-mediated tumor regression in 30%
of cases in both a mouse model for pancreatic cancer
and in patients with pancreatic cancer [112]. CD40 ther-
apy resulted in the stimulation of secondary lymph node
resident macrophages to migrate into the tumor tissue.
Whereas, tumor-infiltrating in non-treated animals pre-
dominantly produced IL-10, the tumor-infiltrating
macrophages of antibody treated mice produced IL-12
[112]. Notably, macrophages already present in the
tumor were not stimulated by this treatment, possibly
due to a low tissue penetration of the antibody [112]. In
vitro CD40-activation with IFNg was required to effec-
tively reprogram tumor-induced M2-like macrophages
into activated IL-12 producing M1 cells (Figure 1). As
CD40 is not only expressed by macrophages but also by
monocytes, endothelial cells, epithelial cells, and B cells
[113], it is likely that the activation of several cell types
throughout the body resulted in the deliverance of the
necessary pro-inflammatory cytokines that allowed the
circulating CD40-activated macrophages to adapt to a
M1 phenotype.
In order to reprogram macrophages directly in the
tumor-microenvironment, it is essential that CD4+ Th1
cells are locally present. The capacity of tumor-specific
Th1 cells to directly alter the tumor microenvironment
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CD8+ T cells in mice models. Th1 cells were essential
for successful recruitment, local expansion and full
effector function of large numbers of CTL by modula-
tion of the local environment [114,115], and this may
have included the repolarization of macrophages. In
order to obtain sufficient numbers of tumor-specific
CD4+ Th1 cells one may make use of adoptive T-cell
transfer protocols [116,117] or apply strong vaccines
[118,119].
Conclusion and prospective
Macrophages play an important role in tumors. Depend-
ing on the mode of activation, they may promote tumor
growth and suppress local immunity or attack tumor
cells and sustain tumor immunity. Immunotherapeutic
strategies to combat cancer should incorporate
approaches focused on the attraction and polarization of
M 1m a c r o p h a g e sa sw e l la so nt h er e p r o g r a m m i n go f
M2 macrophages to the M1 subset. This requires a
well-based understanding of the different subsets of
macrophages in human tumors as well as their interac-
tion with other members of the immune system, includ-
ing T helper cells. To this end, the type and numbers of
macrophages in the tumor have to be more carefully
analyzed by the simultaneous use of several markers
that allow discriminating the different macrophages sub-
sets in one run. New and better subset-specific markers
need to be identified. In addition, it will require in-
depth studies on the interaction of local T cells and
macrophages, a subject which currently is only margin-
ally studied in human cancers.
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